Compare DRCT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | INAB |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.6M |
| IPO Year | 2022 | 2021 |
| Metric | DRCT | INAB |
|---|---|---|
| Price | $0.10 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 27.8M | 59.0K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,369,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $1.53 |
| 52 Week High | $6.59 | $12.53 |
| Indicator | DRCT | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 24.96 | 49.97 |
| Support Level | $0.09 | $1.73 |
| Resistance Level | $0.18 | $2.11 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 8.15 | 51.07 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.